Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Herbst (2010)
The Short-Sighted Value of Inefficiency: Why We Should Mind the Gap in the Reimbursement of Outpatient Prescription DrugsSocial Science Research Network
F. Rodino (2013)
Corporate Integrity Agreements: What They Say About Publications, Publication Planning, Transparency, and ICMJETherapeutic Innovation & Regulatory Science, 47
E. Koski (2005)
Ethics and the Pharmaceutical Industry: Renegotiating the Grand Bargain: Balancing Prices, Profits, People, and Principles
H. Grabowski, M. Kyle (2007)
Generic competition and market exclusivity periods in pharmaceuticalsManagerial and Decision Economics, 28
Fadi Alkhateeb, Patricia Baidoo, Marija Cavana, Danielle Gill, A. Howell, Babak Mehraeen, Carrie Weidner (2011)
Is certification for pharmaceutical sales representatives necessaryInternational Journal of Pharmaceutical and Healthcare Marketing, 5
W. Shrank, N. Choudhry, J. Agnew-Blais, A. Federman, J. Liberman, Jun Liu, A. Kesselheim, M. Brookhart, M. Fischer (2010)
State generic substitution laws can lower drug outlays under Medicaid.Health affairs, 29 7
A. Kesselheim, D. Darby, D. Studdert, R. Glynn, R. Levin, J. Avorn (2011)
False Claims Act prosecution did not deter off-label drug use in the case of neurontin.Health affairs, 30 12
D. Kvesic (2008)
Product Lifecycle Management: Marketing Strategies for the Pharmaceutical IndustryJournal of Medical Marketing, 8
Scott Danzis (2005)
Ethics and the Pharmaceutical Industry: Off-Label Communications and Prescription Drugs
R. Petty (1993)
Advertising and the First Amendment: A Practical Test for Distinguishing Commercial Speech from Fully Protected SpeechJournal of Public Policy & Marketing, 12
J. Herbst (2013)
How Medicare Part D, Medicaid, Electronic Prescribing and ICD-10 Could Improve Public Health (But Only if CMS Lets Them)Political Economy: Government Expenditures & Related Policies eJournal
A. Kesselheim, M. Mello, D. Studdert (2011)
Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower ComplaintsPLoS Medicine, 8
H. Rotfeld (1982)
The Compatibility of Advertising Regulation and the First Amendment—Another ViewJournal of Public Policy & Marketing, 1
Jeffrey Blumer (1999)
Off-label uses of drugs in children.Pediatrics, 104 3 Pt 2
K. Kendall, S. Ng, Bertram Schoner (1991)
Consumer Response to Generic/Chemically Equivalent DrugsJournal of Public Policy & Marketing, 10
E. Berndt (2002)
Pharmaceuticals in U.S. health care: determinants of quantity and price.The journal of economic perspectives : a journal of the American Economic Association, 16 4
G. Sillup, Stephen Porth (2008)
Ethical issues in the pharmaceutical industry: an analysis of US newspapersInternational Journal of Pharmaceutical and Healthcare Marketing, 2
M. Fischer, J. Avorn (2012)
Academic detailing can play a key role in assessing and implementing comparative effectiveness research findings.Health affairs, 31 10
J. Avorn, M. Fischer (2010)
'Bench to behavior': translating comparative effectiveness research into improved clinical practice.Health affairs, 29 10
Purpose – The purpose of the study is to review The False Claims Act (FCA) settlements and challenges facing the industry to suggest the motivation behind firms’ alleged fraudulent activity. FCA has been applied against pharmaceutical companies by the US Government to combat marketing fraud including kickbacks, improper pricing and off-label promotion. The interests of the US Government and medical professionals are also considered. Changes to the law governing pharmaceutical marketing practices are recommended. Design/methodology/approach – Cases settled under the FCA between 2005 and 2012 were identified by accessing the US Department of Health and Human Services (DHHS) Corporate Integrity Agreements Web site and annual reports and the quitamhelp.com Web site. Case details were collected from US Department of Justice press releases, DHHS annual reports, and case documents in the Public Access to Court Electronic Records database. Findings – Of the settled cases in the final sample, improper pricing practices were evident in 33 per cent of the cases; off-label promotion in 52 per cent; and both in 15 per cent of the cases. Forty-eight per cent of the alleged fraudulent marketing activity occurred within the brands’ first year and 68 per cent within the first two years on the market. Reported settlements ranged from US$4 million to US$4.3 billion. Originality/value – This research simultaneously considers business issues facing the pharmaceutical industry and alleged fraudulent marketing activity to recommend changes to the law governing drug promotion. Changes have the potential to improve the balance between the respective interests of industry, medicine and government and to improve compliance and patient care in the future.
International Journal of Pharmaceutical and Healthcare Marketing – Emerald Publishing
Published: Aug 26, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.